MentionFox
Home › Executive changes › Cero Therapeutics Holdings, Inc.
Leadership changes · CERO · SEC Form 8-K, Item 5.02

Leadership changes at Cero Therapeutics Holdings, Inc. (2026)

Before you join, sell to or invest in Cero Therapeutics Holdings, Inc.

MentionFox check on Cero Therapeutics Holdings, Inc.: only 1 source on file so far (checked 14 November 2026). Run a full check before you rely on it. mentionfox.com/c/executive-changes/cero-therapeutics-holdings

Check Cero Therapeutics Holdings, Inc. before you join, sell or invest Free, no sign-up: every record on file, each linked to its source.

What do you want to do about Cero Therapeutics Holdings, Inc.?

Who joined and who left Cero Therapeutics Holdings, Inc. (CERO)? 1 appointment reported on 2026-02-13, each cited to the company's own filing.

Eric Francois was appointed Director of Cero Therapeutics Holdings, Inc., effective February 13, 2026. As of November 14, 2026, Cero Therapeutics Holdings, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on February 13, 2026, naming 1 appointment (Form 8-K, February 13, 2026).

29 companies changed executives this week, 1 had other signals.

Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.

ONITY GROUP INC.announced the departure of its Chief Investment Officer
Adicet Bio, Inc.announced the departure of its Director
MAMMOTH ENERGY SERVICES, INC.announced the departure of its Chief Operating Officer
CERENOME, INC.named a new Director
Cohen & Co Inc.named a new Chief Executive Officer
Check one company free All companies that changed executives this week

Armistice Capital, LLC also filed stake reports on 120 other companies ↓

Sell to companies like Cero Therapeutics Holdings, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Opens in a new tab. No signup.

Changes1
In (appointed)1
Latest filing2026-02-13

Cero Therapeutics Holdings, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-02-13. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Cero Therapeutics Holdings, Inc. files it.

Also on the record for Cero Therapeutics Holdings, Inc.

DateRecordFigureOur pageSource
August 14, 2026Stake report, Schedule 13G/A, by Tibbs Isaiah4.63% of the class5%+ stakesSource
March 12, 2026Stake report, Schedule 13G, by Tibbs Isaiah8.67% of the class5%+ stakesSource
December 5, 2025IPO filing, Form S-1—IPO filingsSource
August 14, 2025Stake report, Schedule 13G/A, by Armistice Capital, LLC4.99% of the class5%+ stakesSource
July 21, 2025IPO filing, Form S-1—IPO filingsSource
May 6, 2025Form D, private offering$5M soldForm D pageSource
February 5, 2025IPO filing, Form S-1/A—IPO filingsSource
January 21, 2025IPO filing, Form S-1/A—IPO filingsSource
December 23, 2024IPO filing, Form S-1—IPO filingsSource
November 27, 2024IPO filing, Form S-1—IPO filingsSource
November 25, 2024IPO filing, Form S-1/A—IPO filingsSource
October 22, 2024IPO filing, Form S-1/A—IPO filingsSource

Selling to them or working with them? See who runs Cero Therapeutics Holdings, Inc. now and the warning signs.

Watch Cero Therapeutics Holdings, Inc.: email me the next time it files something

Free to see. No signup.

Keep reading

More on Cero Therapeutics Holdings, Inc. and the records around it.

Cero Therapeutics Holdings, Inc. elsewhere on the record

Companies that share a holder

Want the whole picture on Cero Therapeutics Holdings, Inc.?

Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)

A Full Report on Cero Therapeutics Holdings, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Cero Therapeutics Holdings, Inc. covers

  1. The Short Answer

  2. Which Company This Is

  3. What They Do, And How The Money Works

  4. Who Runs It, And How To Reach Them

  5. The Money: Funding, Valuation, Runway

  6. Who Pays Them, And Who They Are Up Against

  7. Warning Bells

  8. Sources

    13 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

See a sample report

First screen of a real sample Full Report on EchoStar: the verdict, 17 sections, 63 cited sources, built 2026-10-21A real finished report, first screen. Opens in a new tab.

The newest 12 of 13 records.

Timeline

FiledIn / outPersonRoleEffectiveSource
2026-02-13InDirector2026-02-138-K, 2026-02-13

Who leads Cero Therapeutics Holdings, Inc., as last reported?

For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.

Selling to Cero Therapeutics Holdings, Inc.?

New leaders reset buying decisions — get the Full Report on Cero Therapeutics Holdings, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.

Get the Full Report

Watch Cero Therapeutics Holdings, Inc.

Hiring for a seat like this?

Find people with the same kind of experience as the Director at Cero Therapeutics Holdings, Inc., with the record behind each one.

Find candidates like Director at Cero Therapeutics Holdings, Inc.

Every change, in the filing's words

Filed 2026-02-13 · 8-K

Appointed: Eric Francois, Director, effective 2026-02-13

The board of directors of the Company (the "Board"), approved an increase in the size of the Board from six (6) to seven (7) members and, upon the recommendation of the nominating and corporate governance committee of the Board (the "NCG Committee"), appointed Eric Francois to the newly created seat, in each case, following the acceptance by Mr. Francois of such appointment, effective February 13, 2026.

Also stated in this filing

  • Mr. Francois will serve as a director of the Company until the 2026 Annual Meeting of Stockholders, at which time he is expected to stand for election by the Company's stockholders (the "2026 Annual Meeting").
  • Subject to confirmation of independence by the NCG Committee and the Board, Mr. Francois will also serve as a member of the Audit Committee.
  • Eric Francois was the Managing Director of Raymond James Financial, Inc. between August 2023 and September 2025.
  • Prior to that, he was the Managing Director at Credit Suisse between November 2021 and August 2023.
  • He previously served as Chief Financial Officer at Scynexis, Inc. between November 2015 to November 2021 and was the co-founder and Chief Operating Officer of Topi, Inc., between July 2013 and October 2015.
  • Mr. Francois was an member of board of directors at Diffusion Pharmaceuticals, Inc., between June 2021 and December 2022.
  • Mr. Francois served from September 2007 to July 2013 as a Director in the Equity Capital Markets Group at Lazard Ltd where he led capital raisings and advisory assignments for healthcare and biotechnology companies.
  • He started his career in September 2000 at Cowen and Company in the Equity Capital Markets and Convertible Debt Groups.
  • Mr. Francois holds a B.A. in Economics and Business Administration and a M.A. in Marketing from Pantheon-Sorbonne University, France.

Tools for this story

Each opens in a new tab, filled in for Cero Therapeutics Holdings, Inc.. With no account yet, you sign up free and land on the result.

Where this comes from

A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.

Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.

Not for employment, credit or tenancy decisions. MentionFox research is for sales, partnership and investor research. Permitted use

Cite this page

Permanent URL: https://mentionfox.com/executive-changes/cero-therapeutics-holdings
Last updated 2026-11-14
Primary record: SEC filing 1 · SEC filing 2 · SEC filing 3 · SEC filing 4
Who joined Cero Therapeutics Holdings, Inc.? (2026). MentionFox, 2026-11-14. https://mentionfox.com/executive-changes/cero-therapeutics-holdings